The Take Home Journal

Home » The Take Home Journal

The online response to hematologynews.com has been so favorable that Frontline has decided to also launch a print publication called Hematology News. Now summaries of new studies from the literature and from presentations at medical meetings as well as commentaries and articles on practice economics and health policy will be available in an “analog version” as well as a digital option.

Your initial response to this news might be “why would any digital-first information company add print?”  What I believe you will begin to recognize is that physicians enjoy the “mac and cheese” comforts of a print publication. After a day of endless e-mails and online interactions, hematologists can sit down with a “take home journal” that keeps them up to date with straightforward, thorough, and easy-to-read news articles and commentaries that matter to their practices.

And while I refer to it as the “take home journal,” the goal of Hematology News is not to emulate the original investigations and peer review of a journal. Instead, we will bring you brief, easy-to-read articles that allow you to quickly and comfortably ingest recently reported data, expert commentaries that discuss the relevance of the findings, and editorials to bring you a chuckle or raise your hackles.

Consider which is more valuable to physicians: The scientific journal that contains 3 articles of interest among 20 irrelevant ones, or the “take home journal” that summarizes 20 relevant articles among a wide variety of scientific journals, meeting abstracts, and conference proceedings? The “take home journal” saves physicians time reviewing journals, which all too often pile up in a corner of our offices waiting for us to get to them.

With the pace of advances in hematology, it’s never been more important to keep up. In just the last year, for example, the FDA approved several new agents for the treatment of multiple myeloma. The studies leading to FDA approval are published and available to the interested reader. However, these agents are all approved for patients with relapsed or refractory disease. How should you decide which patients should be treated with which agent? Which combination? What sequence? How are adverse effects managed?  The “take home journal” will provide the context, commentary, and conclusions that physicians will value as they integrate these new treatments into practice.

Our intention is to make keeping up with hematology faster and simpler, and not to add to the stack of unread stuff accumulating in hematologists’ offices.  We want Hematology News to be a fun and engaging read because, let’s face it, hematologists are never going to get to that stack of journals in their offices.

For additional information please contact:

Frank Iorio, Managing Director
Frontline Oncology
Office: 973-206-8990
fiorio@mdedge.com